(Q37777489)

23 August 2017

1 reference

title

Therapeutic options in the management of myeloma bone disease (English)

1 reference

23 August 2017

Therapeutic Options in the Management of Myeloma Bone Disease (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

16 June 2024

author name string

James R. Berenson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682368

16 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20682368

16 June 2024

publication date

1 June 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410000886?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

https://api.elsevier.com/content/article/PII:S0093775410000886?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

16 June 2024

1 reference

23 August 2017

volume

37 Suppl 1

1 reference

23 August 2017

page(s)

S20-9

1 reference

Estimating the world cancer burden: Globocan 2000.

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

16 June 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

16 June 2024

Multiple myeloma

4

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

International staging system for multiple myeloma

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Fracture risk in monoclonal gammopathy of undetermined significance

16 June 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Myeloma bone disease: pathophysiology and management.

16 June 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Management of complications in multiple myeloma

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

16 June 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

The role of Dickkopf-1 in bone development, homeostasis, and disease

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Multiple myeloma: review of 869 cases

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma

16 June 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Costs of multiple myeloma and associated skeletal-related events in The Netherlands

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Therapy of metastatic bone pain

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma

16 June 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Treatment for myeloma bone disease

16 June 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma

16 June 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Treatment of bone tumours by radiofrequency thermal ablation

16 June 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects

16 June 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Vertebroplasty in multiple myeloma: outcomes in a large patient series

16 June 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Kyphoplasty enhances function and structural alignment in multiple myeloma.

16 June 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Bisphosphonates: clinical experience

16 June 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma

16 June 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Bisphosphonate treatment of lytic bone metastases

16 June 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

16 June 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

16 June 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

16 June 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

16 June 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

16 June 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

16 June 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

16 June 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

16 June 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

16 June 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

16 June 2024

52

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

16 June 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

16 June 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Bisphosphonates in multiple myeloma

16 June 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

16 June 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

16 June 2024

61

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

16 June 2024

62

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

16 June 2024

63

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

16 June 2024

64

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates

16 June 2024

65

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome

16 June 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Incidence and pathophysiology of hypercalcemia

16 June 2024

67

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

16 June 2024

68

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

16 June 2024

69

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.009

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference